NEW YORK, Feb 21 – Lynx Therapeutics reported a 37 percent drop in fourth-quarter 2000 revenues to $3.3 million, compared with $10.1 million in the year ago quarter, as revenues from technology access and service fees as well as collaborative research fell.

In the fourth quarter, Lynx posted revenues from technology access and service fees of $3.2 million, compared with $5.1 million in fourth-quarter 1999. Revenues from collaborative research plummeted to $125,000, from $5.0 million in the year ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.